AzTrials
AzTrials

Alcohol Use DisorderNCT02994043

Alcohol, Inflammation, and Mindfulness Study (AIM)

A study testing Mindfulness-Based Relapse Prevention Therapy and Relapse Prevention Therapy in people with Alcohol Use Disorder, run by University of Colorado, Denver at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The goal of the AIM Study is to examine the effectiveness of Mindfulness Based Relapse Prevention (MBRP) versus Relapse Prevention (RP) for the treatment of Alcohol Use Disorders (AUD) by implementing an 8-week long intervention and examining neurobiological, immunological, and epigenetic characteristics of AUD. Read more about this study

Who is it for?
Ages 21 to 60 years
Conditions the study is for
Alcohol Use Disorder
What is being tested?
Mindfulness-Based Relapse Prevention Therapy and Relapse Prevention Therapy
Could I receive a placebo?
No, everyone receives an active treatment
How many people
182 participants
Where
1 siteUnited States
Study dates
9 Nov 2016to 17 Feb 2021
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 to 60 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Have a primary Diagnostic Statistical Manual-V (DSM-V) diagnosis of alcohol use disorder;
  • Must be within 10 days of last drink;
  • Must have been drinking heavily (criteria dependent upon individual?s age, gender, and BMI) for a consistent period of time;
  • Must have a breath alcohol level of 0 at screening;
  • Must have a Clinical Institute Withdrawal Assessment (CIWA) score less than 8 (indicating no need for medical detox);
  • Must have expressed a desire during their initial screen to reduce the number of drinks they regularly consume

Who cannot join

  • Currently taking any medications for the treatment of psychiatric disorders, including substance use disorders, mood disorders, and psychosis;
  • Pregnant, as indicated by a pregnancy test which will be administered at baseline;
  • Positive for, sedatives, opiates, cocaine, or amphetamine on drug screen at baseline;
  • Meets criteria for psychotic disorder, bipolar disorder, or a major depressive episode

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of Colorado Denver

    Denver, Colorado, 80045

Other trials in United States

About this study

Official title: Dismantling MBRP: Identifying Critical Neuroimmune Mechanisms of Action.

The goal of the AIM Study is to examine the effectiveness of Mindfulness Based Relapse Prevention (MBRP) versus Relapse Prevention (RP) for the treatment of Alcohol Use Disorders (AUD) by implementing an 8-week long intervention and examining neurobiological, immunological, and epigenetic characteristics of AUD.

Read the detailed description

This study was designed to evaluate the effect of two outpatient, individually-administered, psychosocial interventions (Relapse Prevention vs. Mindfulness-Based Relapse Prevention). Participants are recruited via mass media advertisements, flyers, and local outreach to clinical providers that do not address substance use. We will recruit 226 individuals. Our previous experience with clinical trials, as well as the experience of our research team members with these interventions support the feasibility of recruiting approximately 50 patients per year. This sample size provides adequate statistical power for the research questions undertaken.

Participants are screened over the telephone and invited into the laboratory for a baseline assessment. Immediately after the baseline assessment, they are randomized to a therapist and then to a treatment condition. At the end of each year, the distribution of participants across conditions and therapists are evaluated for imbalances. If attrition has resulted in an imbalance across conditions, the randomization procedure will be adjusted to ensure equal numbers of participants in RP and MBRP.

Within a week of completing the baseline assessments, participants are seen by their individual therapist for a motivational interviewing, goal-setting session. After the goal-setting session, the eight-session MBRP or RP treatments are administered. To ensure that therapists adhere to treatment manuals, a checklist is provided consisting of the primary content addressed each session (four to seven primary content pieces each session). Further, questionnaires assessing mindfulness practice and facets of mindfulness (e.g., being nonjudgmental, nonreactive) are administered at each assessment. At the most recent RPPR, these questionnaires validated that participants in the MBRP condition were increasing in some facets of mindfulness during treatment (and up to three months after treatment).

We estimate that the completion of assessments and procedures across the duration of the trial, excluding therapy sessions, will total about 15 hours of time. To compensate subjects for their time and travel costs, each subject will be paid $300 if they complete all sessions.

We will conduct extensive analyses of any attrition encountered in the project to determine bias. However, note that in each of the analyses described herein, we will have the capability of using modern approaches to the handling of missing data including full information maximum likelihood estimation of missing data within Proc Mixed in SAS and within EQS.

The distributional properties of all continuously scaled variables will be examined for skewness and kurtosis to determine the need for normalizing transformations or for alternations to our analysis plan (i.e., generalized estimating equations or robust estimation) prior to the primary analyses.

To confirm the validity of random assignment, pretest equivalence of the two treatment conditions across demographics, drinking history, smoking, and all other baseline measures will be assessed via t-tests on continuous items and c2 tests of categorical items. We will use the Bonferroni approach to correct for alpha inflation with a familywise alpha of .05. Any variables on which the two groups are unequal at pretest will be covariates in all further analyses.

Attrition analyses will be conducted after each follow-up data collection effort to provide assurance that differential attrition by treatment condition has not occurred. Following previously published procedures, a series of ANOVAs of treatment (MBRP versus RP) X retention (retained, not retained) will be conducted on continuous baseline measures. Significant treatment X retention interactions identify measured variables on which differential attrition may have occurred. The logit model analog procedure will be applied to categorical baseline measures to test for differential attrition on categorical variables such as gender and ethnicity. We will conduct these analyses to assure that differential attrition by treatment condition does not account for any of the effects of the treatments.

Being tested
Mindfulness-Based Relapse Prevention Therapy, Relapse Prevention Therapy
Medical subject headings
Alcoholism

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Mindfulness-Based Relapse Prevention TherapyBehavioural

    An 8-week, outpatient psychotherapy that combines mindfulness components with relapse prevention.

  • Relapse Prevention TherapyBehavioural

    An 8-week, outpatient psychotherapy that uses cognitive-behavioral components to reduce alcohol-related consequences.

Study groups in NCT02994043
Study groupRoleWhat they receive
MBRPActive comparatorNot described
Receives: Behavioral: Mindfulness-Based Relapse Prevention Therapy
RPActive comparatorNot described
Receives: Behavioral: Relapse Prevention Therapy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Heavy Drinking Days at Baseline

    Timeline Follow-back (TLFB) measure of heavy drinking days in the last month (4+ for women, 5+ for men)

    Measured: Baseline

  2. Heavy Drinking Days at Week 4

    Timeline Follow-back (TLFB) measure of heavy drinking days in the last month (4+ for women, 5+ for men)

    Measured: Week 4

  3. Heavy Drinking Days at Week 8

    Timeline Follow-back (TLFB) measure of heavy drinking days in the last month (4+ for women, 5+ for men)

    Measured: Week 8

  4. Heavy Drinking Days at Week 20

    Timeline Follow-back (TLFB) measure of heavy drinking days in the last month (4+ for women, 5+ for men)

    Measured: Week 20

  5. Heavy Drinking Days at Week 32

    Timeline Follow-back (TLFB) measure of heavy drinking days in the last month (4+ for women, 5+ for men)

    Measured: Week 32

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Dec 2016 (estimated)
  2. Study start9 Nov 2016
  3. Primary completion17 Feb 2021
  4. Study completion17 Feb 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
182 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02994043
Sponsor's protocol ID
20-2550
Other IDs
R01AA024632
Status last verified
Dec 2022
First submitted
12 Dec 2016
Last updated
19 Jan 2023
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Skrzynski CJ, Karoly H, Ellingson JM, Hagerty SL, Bryan AD, Hutchison KE. Comparing the Efficacy of Mindfulness-Based Relapse Prevention Versus Relapse Prevention for Alcohol Use Disorder: A Randomized Control Trial. J Stud Alcohol Drugs. 2023 Jul;84(4):560-569. doi: 10.15288/jsad.21-00392. Epub 2023 Feb 1.

    PubMed 36971735
  • Karoly HC, Skrzynski CJ, Moe EN, Bryan AD, Hutchison KE. Exploring relationships between alcohol consumption, inflammation, and brain structure in a heavy drinking sample. Alcohol Clin Exp Res. 2021 Nov;45(11):2256-2270. doi: 10.1111/acer.14712. Epub 2021 Sep 22.

    PubMed 34523725
  • Karoly HC, Ross JM, Prince MA, Zabelski AE, Hutchison KE. Effects of cannabis use on alcohol consumption in a sample of treatment-engaged heavy drinkers in Colorado. Addiction. 2021 Sep;116(9):2529-2537. doi: 10.1111/add.15407. Epub 2021 Jan 26.

    PubMed 33464670

Questions about this trial

What is this clinical trial studying?

A study testing Mindfulness-Based Relapse Prevention Therapy and Relapse Prevention Therapy in people with Alcohol Use Disorder, run by University of Colorado, Denver at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 19 Jan 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 19 Jan 2023). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Heavy Drinking Days at Baseline (time frame: Baseline). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02994043, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Jan 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in